AQST all pull backs can be used as new buying opportunities.
FDA Type C Meeting
The Company also successfully completed a Type C meeting with the FDA that addressed open items from the November 2022 End-of-Phase 2 meeting including addressing (1) the impact of any product hold time, (2) the potential for emesis (vomiting), and (3) the impact of potential mouth...
AQST: Aquestive Therapeutics, Inc.
2022-02-25 07:00:00
Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine
AQST: Aquestive Therapeutics, Inc.
2022-02-25 07:00:00
Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
AQST: Aquestive Therapeutics, Inc.
2021-10-25 08:31:00
Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergi
Wkly falling wedge setting up for a market structure break and rest to start a 5 wave move possibly. looking for a clearance of the Dec 2, 2019 orderblock for long-term growth
You guys know I love biotechs with press releases coming up. I also like to wait to enter until the charts look bullish. Aquestive Therapeutics fell from $8 to $4 in September 2020, and I think they could pull back eventually, regardless of press releases. Now that they have an approval coming up on the second, I expect them to perform phenomenally for the rest of...
Contextual immersion trading strategy idea.
Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs.
The share price rose after good earnings. I see some preconditions the share price will continue growing.
The demand for shares of the company still...
NASDAQ:AQST
😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks
Our Strategy with this Stock :
the company will release the drug for Parkinson disease treatment,
The analysts are writing the stock at $17 to drive the sheep to buy the stock , while safe Traders will look for a high price of 6.18 $ .
I'm putting two alarms, one at 4.79 to...
